CD19 and diffuse large B-cell lymphoma: Moreover, B-NHL co-cultures (DLBCL lines: Pfeiffer and Karpas422; BL; Raji, Daudi; FL: RL) showed that ADCC and ADCP induced by a CD47- and CD19-targeting bispecific antibody (TG-1801) was enhanced when it was used in a “U2-regimen” (with anti-CD20-mAb: ubilituximab; and PI3Kδ/CK1e inhibitor: umbralisib) than in monotherapy [85].